natgillin/translations-raw huggingface dataset:
Paroxetine is associated with withdrawal reactions which can be severe in intensity and prolonged in duration. 
Paroksetin je povezan z odtegnitvenimi reakcijami, ki so lahko močno intenzivne in dolgo trajajo.
Paroxetine should not be used in the treatment of children and adolescents under the age of 18 years. 
Paroksetin se ne sme uporabljati za zdravljenje otrok in mladostnikov mlajših od 18 let.
Suicide/suicidal ideation 
Samomor/samomorilna miselnost
During the decision-making process for the article 31 referral on paroxetine subsequent to the CHMP opinion of 22 April 2004, UK informed the European Commission that three new studies with direct relevance to this issue had become available. 
Med procesom odločanja v okviru obravnave učinkovine paroksetin v skladu s 31. členom, ki je sledilo mnenju CHMP z dne 22. aprila 2004, je Združeno kraljestvo obvestilo Evropsko komisijo, da so bili dani na razpolago rezultati treh novih raziskav, ki se neposredno tičejo obravnavane tematike.
Currently paroxetine is not authorised for use in children and adolescents in any EU Member State. 
Trenutno paroksetina ni dovoljeno uporabljati pri otrocih in mladostnikih v nobeni od držav članic EU.
As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. 
Ker je možno, da med prvimi nekaj tedni zdravljenja ne pride do izboljšanja, je potrebno bolnike skrbno nadzorovati vse dokler ne pride do izboljšanja.
Women planning a pregnancy and those becoming pregnant during therapy should be asked to consult their physician. 
Ženske, ki nameravajo zanositi in ženske, ki med zdravljenjem zanosijo se morajo posvetovati z zdravnikom.
In view of the above the CHMP confirmed its previous conclusions in relation to the risk of suicidal behaviour in patients using paroxetine. 
Z ozirom na zgoraj navedeno je CHMP potrdil svoje prejšnje sklepe glede tveganja za samomorilno vedenje pri bolnikih, ki uporabljajo paroksetin.
• Member States should ensure that appropriate pharmaceutical forms / strengths can be made available in order to facilitate up and down titration in accordance to the posology recommendations stated in the SPC attached to Annex III of this Opinion. 
• Države članice morajo zagotoviti razpoložljivost ustreznih farmacevtskih oblik / jakosti, da pospešimo višanja in nižanja odmerkov v skladu s priporočili za odmerjanje, navedenimi v SPC, priloženemu Dodatku III tega Mnenja.
Tecnimede - Sociedade TécnicoMedicinal, S.A. 
Portugalska Tecnimede - Sociedade TécnicoMedicinal, S.A.
However, in a significant proportion of individuals they may be severe in intensity and of prolonged duration (2-3 months or more). 
Vendar pa so pri pomembnem deležu bolnikov ti lahko resne jakosti in podaljšanega trajanja (2-3 mesece ali dlje).
These studies investigated the risk of suicidal behaviours (including completed suicides, suicide attempts and suicidal ideation) associated with the use of various antidepressants. 
Te raziskave so proučevale tveganje za samomorilno vedenje (vključno z izvedenimi samomori, poskusi samomora in samomorilnim razmišljanjem), povezano z uporabo različnih antidepresivov.
The activating properties are not "amphetamine-like" in nature. 
Te lastnosti po svoji naravi niso "podobne lastnostim amfetamina".
In patients who develop these symptoms, increasing the dose may be detrimental. 
Pri bolnikih pri katerih se pojavijo ti simptomi je povečevanje odmerka lahko škodljivo.
PHARMACEUTICAL PARTICULARS 6.1 List of Excipients [To be completed nationally] 6.2 Incompatibilities [To be completed nationally] 6.3 Shelf-life [To be completed nationally] 6.4 Special precautions for storage [To be completed nationally] 6.5 Nature and contents of container [To be completed nationally] 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi [potrebno dopolniti lokalno] 6.2 Inkompatibilnosti [potrebno dopolniti lokalno] 6.3 Rok uporabnosti [potrebno dopolniti lokalno] 6.4 Posebna navodila za shranjevanje [potrebno dopolniti lokalno] 6.5 Vrsta ovojnine in vsebina [potrebno dopolniti lokalno] 6.6 Navodila za pripravo in ravnanje z zdravilom [potrebno dopolniti lokalno]
From the assessed data there was no indication of a signal of dependence with paroxetine. 
V ocenjenih podatkih ni bilo indikacije za znake odvisnosti pri paroksetinu.
The CHMP noted that long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking. 
V CHMP so opazili, da manjkajo podatki o varnosti na dolgi rok pri otrocih in mladostnikih v zvezi z rastjo, odraščanjem, kognitivnim in vedenjskim razvojem.
Rates in patients with other disorders for which paroxetine is indicated are similarly low. 
Stopnje pri bolnikih z drugimi motnjami, za katere je paroksetin indiciran, so podobno nizke.
The treatment should consist of those general measures employed in the management of overdose with any antidepressant. 
Zdravljenje mora obsegati tiste splošne ukrepe, ki se uporabljajo pri prevelikem odmerjanju katerega koli antidepresiva.
The CHMP considered that despite some problems in the studies, mainly related to the fact that many patients suffered from co-morbid depression, there is evidence to support the efficacy in this indication, however the long-term efficacy has not been sufficiently demonstrated. 
V CHMP so menili, da kljub določenim težavam v študijah, povezanih zlasti z dejstvom, da je imelo veliko bolnikov komorbidno depresijo, obstajajo podatki, ki potrjujejo učinkovitost pri tej indikaciji, vendar pa dolgoročna učinkovitost ni bila zadostno dokazana.
The issue of suicidal behaviour among patients treated with paroxetine has been addressed in the past in literature and at national level in some Member States. 
V preteklosti so se problema samomorilnega vedenja med bolniki, zdravljenimi s paroksetinom,v nekaterih državah članicah lotili v literaturi in na nacionalni ravni.
Toxicology studies have been conducted in rhesus monkeys and albino rats; in both, the metabolic pathway is similar to that described for humans. 
Toksikološke študije so bile opravljene na opicah rhesus in na albino podganah; pri obeh vrstah je pot presnove podobna kot pri ljudeh.
The CHMP discussed in particular whether higher doses may be necessary for some patients and can be justified by the available data. 
V CHMP so razpravljali zlasti o tem, ali so pri določenih bolnikih morda potrebni višji odmerki in ali razpoložljivi podatki to opravičujejo.
Immune system disorders Very rare: allergic reactions (including urticaria and angioedema). 
Bolezni imunskega sistema Zelo redki: alergijske reakcije (vključno z urtikarijo in angioedemom)
It is not recommended to use paroxetine in combination with metoprolol when given in cardiac insufficiency, because of the narrow therapeutic index of metoprolol in this indication. 
Paroksetina ni priporočljivo uporabljati v kombinaciji z metoprololom, če se le ta daje pri srčni insuficienci, zaradi ozkega terapevtskega indeksa metoprolola pri tej indikaciji.
- The Committee concluded that there are concerns in relation to the safety of paroxetine containing medicinal products. 
- je Odbor zaključil, da glede varnosti zdravil, vsebujočih paroksetin, obstajajo zadržki.
Jaba Farmacêutica, S.A. Edifício Jaba - Rua da Tapada Grande, 2 - Zona Industrial da Abrunheira 
Portugalska Jaba Farmacêutica, S.A. Edifício Jaba - Rua da Tapada Grande, 2 - Zona Industrial da Abrunheira
Patients, (and caregivers of patients) should be alerted about the need to monitor for the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. 
Bolnike (in skrbnike bolnikov) je potrebno opozoriti na potrebo po nadzoru glede pojava samomorilne miselnosti/vedenja ali misli o samouničevalnosti in da se morajo v primeru pojava teh simptomov nemudoma posvetovati z zdravnikom.
Glaxo Smith Kline Kft. 1124 Bp. Csörsz u. 43. 
Madžarska Glaxo Smith Kline Kft. 1124 Bp. Csörsz u. 43.
A low initial starting dose is recommended to minimise the potential worsening of panic symptomatology, which is generally recognised to occur early in the treatment of this disorder. 
Nizek začetni odmerek priporočamo zato, da bi omejili možno poslabšanje panične simptomatologije za katero je znano, da se pojavi v zgodnjem obdobju zdravljenja te motnje.
There was no indication of a signal of dependence of paroxetine, but long-term data are not available. 
Indikacij znakov odvisnosti od paroksetina ni bilo, vendar podatkov po dolgotrajni uporabi ni na razpolago.
In general these events are mild to moderate, occur within the first week of cessation of treatment and resolve within two weeks. 
V splošnem so ti učinki blagi do zmerni, pojavijo se v prvem tednu po ukinitvi zdravljenja in minejo v roku dveh tednov.
Uncommon: confusion, hallucinations. 
Občasni: zmedenost, halucinacije
Farma APS - Produtos Farmacêuticos, 
Portugalska Farma APS - Produtos Farmacêuticos,
Suicidal thoughts and suicide attempts were mainly observed in clinical trials of adolescents with Major Depressive Disorder. 
Samomorilne misli in poskusi so bili opaženi predvsem v kliničnih raziskavah pri mladostnikih s hudo depresivno motnjo.
Paroxetine should not be used, as long as safety and efficacy in this age group have not been established. 
Dokler ne bosta ugotovljeni varnost in učinkovitost se paroksetin pri tej starostni skupini ne sme uporabljati.
Other psychiatric conditions for which paroxetine is prescribed can also be associated with an increased risk of suicidal behaviour. 
Druga stanja v psihiatriji pri katerih se predpisuje paroksetin so tudi lahko povezana s povečanim tveganjem za samomorilno vedenje.
- Increased suicidal related behaviours in children and adolescents was already seen in the clinical trials and post-marketing data and therefore the CHMP did not consider that the new data added new evidence on this regard. 
- Povečanje samomorilnega vedenja pri otrocih in mladostnikih je že bilo opaženo med kliničnimi preizkušanji in v okviru študij po izdaji dovoljenja za promet, zato CHMP meni, da novi podatki ne prinašajo novih spoznanj na tem področju.
If anti-cholinergic effects are seen, the dose of procyclidine should be reduced. 
Če se opazi antiholinergični učinek je potrebno odmerek prociklidina zmanjšati.
Generis Farmacêutica, S.A. Rua José Galhardo n o. 3, 
Portugalska Generis Farmacêutica, S.A. Rua José Galhardo n o. 3,
Where appropriate, the stomach should be emptied either by the induction of emesis, lavage or both. 
Kadar je primerno je potrebno izprazniti želodec bodisi z izzvanim bruhanjem bodisi z izpiranjem ali na oba načina.
Furthermore in one of the studies the relation between suicidality risk in relation to the indication was investigated. 
Nadalje je ena izmed teh raziskav obravnavala povezavo med indikacijo in tveganjem za samomorilnost.
Procyclidine: Daily administration of paroxetine increases significantly the plasma levels of procyclidine. 
Prociklidin: Dnevno dajanje paroksetina znatno poveča plazemske vrednosti prociklidina.
About 36% of the dose is excreted in faeces, probably via the bile, of which unchanged paroxetine represents less than 1% of the dose. 
Okrog 36 % odmerka se izloči z blatom, verjetno preko žolča, od česar predstavlja nespremenjeni paroksetin manj kot 1 % odmerka.
Paroxetine should be discontinued in any patient entering a manic phase. 
Paroksetin je potrebno ukiniti pri bolnikih, ki prehajajo v manično fazo.
<Parabens> <Paroxetine oral suspension contains methyl and propyl hydroxybenzoate (parabens), which are known to cause urticaria; generally delayed type reactions, such as contact dermatitis, but rarely immediate reaction with bronchospasm.> [To be completed nationally]. 
<Parabeni> <Peroralna suspenzija paroksetina vsebuje metil- in propilhidroksibenzoat (parabena), ki sta znana povzročitelja urtikarije; običajno odložen tip reakcij, kot na primer kontaktni dermatitis, redko pa takojšnja reakcija z bronhospazmom.> [potrebno dopolniti lokalno]
The use of paroxetine has not been studied in children less than 7 years. 
Uporaba paroksetina pri otrocih mlajših od 7 let ni bila raziskana.
As with other psychotropic drugs patients should be advised to avoid alcohol use while taking paroxetine. 
Tako kot pri drugih psihotropnih zdravilih je potrebno bolnikom svetovati, da se naj med jemanjem paroksetina izogibajo pitju alkohola.
Studies indicate that, in contrast to antidepressants which inhibit the uptake of noradrenaline, paroxetine has a much reduced propensity to inhibit the antihypertensive effects of guanethidine. 
Študije kažejo, da je, v nasprotju z antidepresivi, ki zavirajo prevzem noradrenalina, nagnjenost paroksetina k zaviranju antihipertenzivnih učinkov gvanetidina veliko manjša.
The CHMP also considered the available data supporting the recommended posology for each of the above indications. 
V CHMP so upoštevali tudi razpoložljive podatke, potrjujoče priporočeno odmerjanje za vsako od zgornjih indikacij.
The principal metabolites of paroxetine are polar and conjugated products of oxidation and methylation which are readily cleared. 
Glavni presnovki paroksetina so polarni in konjugirani produkti oksidacije in metiliranja, ki se z lahkoto očistijo.
Review of the wording with regards to the possibility of increasing the recommended dose if after some weeks of treatment on the recommended dose insufficient response is seen. 
Pregled besedila glede možnosti povečanja priporočenega odmerka po nekaj tednih zdravljenja, v kolikor ni opaziti zadostnega odziva na priporočeni odmerek.
NAME OF MEDICINAL PRODUCT {INVENTED NAME} {Strength} {Pharmaceutical form} [To be completed nationally] 
IME ZDRAVILA {LASTNIŠKO IME ZDRAVILA} {jakost} {farmacevtska oblika} [potrebno dopolniti lokalno]
Efficacy in children 
Učinkovitost pri otrocih
Anticonvulsants: carbamazepine, phenytoin, sodium valproate. 
Antiepileptiki: karbamazepin, fenitoin, natrijev valproat.
As expected with lipophilic amines, including tricyclic antidepressants, phospholipidosis was detected in rats. 
Kot je pričakovati pri lipofilnih aminih, vključno s tricikličnimi antidepresivi, je pri podganah prišlo do fosfolipidoze.
On 13 June 2003, UK triggered a referral to the EMEA under Article 31 of Directive 2001/83/EC, as amended, to medicinal products containing paroxetine. 
13. junija 2003 je Velika Britanija sprožila napotilo EMEA po 31. členu Direktive 2001/83/ES, kot je bila dopolnjena, za zdravila, vsebujoča paroksetin.
The incidence of possible suicide-related events and selfharm in the paroxetine group were 2-3 times that seen in the placebo group, while hostility events in the paroxetine occurred with a frequency 6 times that seen in the placebo group. 
Pojavnost možnih s samomorom povezanih dogodkov in samopoškodovanja v skupini paroksetina je bila 2-3-kratnik videne v skupini placeba, sovražni dogodki pa so se v skupini s paroksetinom pojavljali s 6-kratnikom pogostnosti, sicer videne v skupini placeba.
This period may be several months or even longer (see section 5.1 Pharmacodynamic Properties) 
Zdravljenje lahko traja nekaj mesecev ali celo več (glejte poglavje 5.1 Farmakodinamične lastnosti).
Animal studies showed reproductive toxicity, but did not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see Section 5.3 Preclinical Safety Data). 
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja, ne kažejo pa na neposreden škodljiv vpliv na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte poglavje 5.3 Predklinični podatki o varnosti).
In view of their relative lack of pharmacological activity, it is most unlikely that they contribute to paroxetine's therapeutic effects. 
Glede na to, da so relativno farmakološko neaktivni je malo verjetno, da bi prispevali k terapevtskemu učinku paroksetina.
Administration of thioridazine alone can lead to QTc interval prolongation with associated serious ventricular arrhythmia such as torsades de pointes, and sudden death. 
Dajanje tioridazina samega lahko povzroči podaljšanje intervala QTc s pridruženo resno ventrikularno aritmijo, kot je torsades de pointes, in nenadno smrt.
The CHMP reviewed available data from published literature and spontaneous reports in relation to withdrawal reactions in neonates whose mothers used paroxetine during pregnancy. 
V CHMP so pregledali razpoložljive podatke iz objavljene literature in spontanih poročil v zvezi z odtegnitvenimi reakcijami pri novorojenčkih, katerih matere so v nosečnosti uporabljale paroksetin.
Data on a limited number of exposed pregnancies provide no indication of an increased risk of congenital malformations in the newborn. 
Podatki zbrani pri majhnem številu nosečnic, ki so bile izpostavljene zdravilu ne kažejo na povečano tveganje za pojav kongenitalnih malformacij pri novorojencu.
However, as with all psychoactive drugs, patients should be cautioned about their ability to drive a car and operate machinery. 
Vendar pa je treba bolnike opozoriti, da naj bodo, tako kot pri vseh psihoaktivnih zdravilih, pozorni na svojo sposobnost vožnje in upravljanja strojev.
Increasing the dose might be useful in some patients, but the maximum dose should not exceed 40 mg daily. 
Nekaterim bolnikom lahko koristi povečevanje odmerka, vendar pa največji odmerek ne sme preseči 40 mg dnevno.
If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. 
Če se po znižanju odmerka ali po prekinitvi zdravljenja pojavijo neznosni simptomi, se lahko razmisli o ponovnem zdravljenju s prej predpisanim odmerkom.
In response to these data UK contraindicated the use of paroxetine in children aged 18 years or less with major depressive disorders. 
Kot odziv na te podatke so v Veliki Britaniji kontraindicirali uporabo paroksetina pri otrocih z veliko depresivno motnjo, starih 18 let ali manj.
Paroxetine has low affinity for muscarinic cholinergic receptors and animal studies have indicated only weak anticholinergic properties. 
Paroksetin ima nizko afiniteto za muskarinske holinergične receptorje in raziskave na živalih so pokazale le šibke antiholinergične lastnosti.
Therefore, this SPC may not necessarily represent the current text. 
Zaradi tega je možno, da ta Povzetek glavnih značilnosti zdravila ne predstavlja trenutno veljavnega besedila.
Genthon BV Box 7071 
Nizozemska Genthon BV Box 7071
Any subsequent dosage adjustment should be guided by clinical effect (tolerability and efficacy). 
Pri vseh nadaljnjih prilagajanjih odmerkov je potrebno upoštevati klinično učinkovitost (prenosljivost in učinkovitost).
Steady state systemic levels are attained by 7 to 14 days after starting treatment with immediate or controlled release formulations and pharmacokinetics do not appear to change during long-term therapy. 
Ravnotežno stanje sistemskih vrednosti je doseženo 7 do 14 dni po začetku zdravljenja z oblikami s takojšnim ali prirejenim sproščanjem; pri dolgotrajnem zdravljenju ni opaziti spremenjenih farmakokinetičnih lastnosti.
As a consequence, the CHMP has recommended the maintenance of the Marketing Authorisations for paroxetine containing medicinal products referred in Annex I as amended in accordance with the SPC set out in Annex III and under the conditions set out in Annex IV. 
Zato je CHMP priporočil vzdrževanje Dovoljenj za promet za zdravila, vsebujoča paroksetin, navedena v Dodatku I, dopolnjena v skladu z SPC v Dodatku III, ter pod pogoji, navedenimi v Dodatku IV.
Significant and relevant results were obtained in the short-term studies but not in the long-term studies and therefore the CHMP concluded that the long-term efficacy has not been sufficiently demonstrated. 
V kratkotrajnih študijah so dobili značilne in pomembne rezultate, ne pa tudi v dolgotrajnih študijah, zato so v CHMP zaključili, da dolgoročna učinkovitost ni bila zadostno dokazana.
In addition, these conditions may be co-morbid with major depressive disorder. 
Razen tega pa se ta stanja lahko pojavljajo sočasno s hudo depresivno motnjo.
Hyponatraemia has been reported predominantly in elderly patients and is sometimes due to syndrome of inappropriate anti-diuretic hormone secretion (SIADH). 
O hiponatriemiji so poročali predvsem pri starejših bolnikih in je včasih povezana s sindromom neustreznega izločanja antidiuretičnega hormona (SIADH).
Therefore the CHMP considered that the benefit/risk balance of paroxetine containing medicinal products in the agreed indications is favourable and the Marketing Authorisations should be maintained in accordance with the: 
Zato so v CHMP sklenili, da je razmerje koristi/tveganja zdravil, vsebujočih paroksetin, za dogovorjene indikacije ugodno ter da naj se Dovoljenja za promet z zdravilom ohranijo v skladu s:
Suicidal related behaviours associated with paroxetine in the clinical trials were more clearly seen in the depression studies than in studies of OCD or SAD. 
Samomorilna povezana vedenja, povezana s paroksetinom, v kliničnih preskušanjih, so bolj očitno opažali v študijah depresije kot v študijah OCD ali SAD.
The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. 
Tveganje za pojav odtegnitvenih simptomov je lahko odvisno od različnih dejavnikov vključno s trajanjem zdravljenja, odmerkom in obsegom zmanjševanja odmerka.
Suicidal behaviour, self-harm and hostility 
Samomorilno vedenje, samopoškodovanje in sovražno razpoloženje Odrasli
- The Committee considered the referral made under article 31 of Directive 2001/83/EC, as amended, for paroxetine containing medicinal products. 
- je Odbor upošteval napotilo pod 31. členom Direktive 2001/83/EC, kot je bilo dopolnjeno, za zdravila, vsebujoča paroksetin.
Withdrawal reactions 
Odtegnitvene reakcije
Inhibition of CYP2D6 may lead to increased plasma concentrations of coadministered drugs metabolised by this enzyme. 
Zaviranje CYP2D6 lahko privede do povečanih plazemskih koncentracij sočasno uporabljenih zdravil, ki jih presnavlja ta encim.
On the basis of the new assessed data the CHMP concluded the following: - The new evidence from the GPRD studies is more vulnerable to various biases, e.g. confounding by indication, compared to evidence coming from clinical trials. 
Na podlagi na novo obravnavanih podatkov je CHMP sklenil naslednje: - Novi dokazi na podlagi GPRD-raziskav so v primerjavi z dokazi iz kliničnih raziskav bolj občutljivi za različne odklone, kot je npr. zamenjana indikacija.
In May 2003 UK reviewed data from clinical trials with paroxetine in the treatment of paediatric OCD, SAD and MDD and concluded that these data provided evidence of an association between the use of paroxetine and an increased risk of emotional lability including self-harm, hostility and suicidal behaviour in children and adolescents. 
Maja 2003 so v Veliki Britaniji pregledali podatke iz kliničnih preskušanj paroksetina pri zdravljenju pediatričnih OCD, SAD in MDD ter zaključili, da ti podatki kažejo na povezavo med uporabo paroksetina in povečanim tveganjem za čustveno labilnost, vključujoč samopoškodovanje, sovražno in samomorilno vedenje pri otrocih in mladostnikih.
Therefore, dosage should be restricted to the lower end of the dosage range. 
Pri odmerjanju se je torej potrebno omejiti na spodnjo mejo odmernega intervala.
• Pregnancy and Lactation 
• Nosečnost in dojenje
PHARMACEUTICAL FORM <Tablet> <Coated tablet> <Film-coated tablet> <Oral solution> <Oral suspension> 
FARMACEVTSKA OBLIKA <Tableta> <Obložena tableta> <Filmsko obložena tableta> <Peroralna raztopina> <Peroralna suspenzija>
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION [To be completed nationally] 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET [potrebno dopolniti lokalno]
Paroxetine is a phenylpiperidine derivative and is a potent and selective inhibitor of the presynaptic 5hydroxytryptamine (5-HT) reuptake. 
Paroksetin je fenilpiperidinski derivat ter močan in selektivni zaviralec presinaptičnega ponovnega privzema 5-hidroksitriptamina (5-HT).
Bexal Produtos Farmacêuticos S.A. Rua Prof. Ricardo Jorge, 5 AMiraflores 
Portugalska Bexal Produtos Farmacêuticos S.A. Rua Prof. Ricardo Jorge, 5 AMiraflores